Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

22
Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
22
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

753
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
753
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

876
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
876

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ingested (oral) adrenocorticotropic hormone (ACTH) inhibits interleukin-17 in the central nervous system after adoptive transfer of T helper (Th)1/Th17 T cells in the mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis.

Journal of the neurological sciences·2023
Same author

The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica.

Autoimmunity reviews·2022
Same author

Ingested (Oral) Adrenocorticotropic Hormone Inhibits IL-17 in the Central Nervous System in the Mouse Model of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.

ImmunoHorizons·2022
Same author

Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer's Disease.

Journal of Alzheimer's disease : JAD·2021
Same author

A proposal: How to study pro-myelinating proteins in MS.

Autoimmunity reviews·2021
Same author

Immune reconstitution therapy in NMOSD.

Multiple sclerosis and related disorders·2021
Same journal

The multifaceted role of acetamide derivative of chalcone: Anti-inflammatory action and impact on osteoclastogenesis, insights on NF-κB and MAPK pathway.

Cytokine·2026
Same journal

Icariin alleviates ovariectomy-induced osteoporosis by promoting M2 macrophage polarization and suppressing osteoclast activation.

Cytokine·2026
Same journal

Single-cell profiling of the immune landscape at the maternal-fetal interface in unexplained recurrent miscarriage.

Cytokine·2026
Same journal

EGFR as a context-dependent modulator of endothelial inflammation: A systematic review.

Cytokine·2026
Same journal

Harnessing the Power of IL-12: Revolutionizing Cancer Therapy with Combinatorial Strategies.

Cytokine·2026
Same journal

Corrigendum to "CCL17 and CCL19 are markers of disease progression in alveolar echinococcosis" [Cytokine 181 (2024) 156669].

Cytokine·2026
See all related articles

Related Experiment Video

Updated: Apr 29, 2026

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.6K

Ingested (oral) tocilizumab inhibits EAE.

Staley A Brod1, Victoria L Bauer1

  • 1Department of Neurology, University of Texas-Houston, Health Science Center, 6431 Fannin St, Houston, TX 77030, United States.

Cytokine
|May 22, 2014
PubMed
Summary
This summary is machine-generated.

Oral administration of tocilizumab (TCZ), an antibody targeting IL-6, effectively reduced inflammation and disease progression in an EAE mouse model. This suggests TCZ

Keywords:
Adoptive transferAntibodyEAEOral proteinsTocilizumab

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

17.7K

Related Experiment Videos

Last Updated: Apr 29, 2026

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.6K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

17.7K

Area of Science:

  • Immunology and Neuroscience
  • Autoimmune Disease Research

Background:

  • Interleukin-6 (IL-6) plays a critical role in autoimmune conditions like rheumatoid arthritis and Crohn's disease.
  • Targeting IL-6 activity is a recognized strategy for managing autoimmune pathologies.

Purpose of the Study:

  • To investigate the efficacy of orally administered tocilizumab (TCZ), an IL-6 inhibitor, in a mouse model of experimental autoimmune encephalomyelitis (EAE).
  • To determine if TCZ exhibits anti-inflammatory effects comparable to its clinical use in rheumatoid arthritis.

Main Methods:

  • Mice with MOG peptide-induced EAE were orally administered TCZ or saline during active disease.
  • Splenocytes, T cells, and myeloid cells from TCZ-treated mice were adoptively transferred to recipient mice.
  • Disease inhibition, central nervous system (CNS) inflammation, and cytokine profiles were analyzed.

Main Results:

  • Oral TCZ administration significantly inhibited ongoing EAE and reduced neuroinflammation.
  • Adoptive transfer of cells from TCZ-treated donors conferred protection against EAE.
  • TCZ treatment decreased pro-inflammatory cytokines (IL-6, TNF-α, IL-12) and increased anti-inflammatory IL-10.

Conclusions:

  • Orally administered TCZ effectively suppresses autoimmune disease activity and CNS inflammation.
  • TCZ treatment modulates cytokine profiles, decreasing Th1-associated cytokines and enhancing Th2-associated cytokines.